Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
10/2002
10/10/2002WO2001098353A3 Secreted proteins
10/10/2002WO2001077174A3 Human transporters and ion channels
10/10/2002US20020147346 New crystal modification of torasemide
10/10/2002US20020147344 Indolylpiperidine derivatives as antihistaminic and antiallergic agents
10/10/2002US20020147341 Kinase inhibitor; benign prostatic hyperplasia
10/10/2002US20020147339 5-cyano-2-aminopyrimidine derivatives
10/10/2002US20020147336 Glucocorticoid receptor modulators
10/10/2002US20020147238 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using R(-)-ketoprofen
10/10/2002US20020147231 Allosteric adenosine receptor modulators
10/10/2002US20020147224 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
10/10/2002US20020147211 Synergistic mixture of angiotensin inhibitors, boric acid, ethylenediaminetetraacetic acid and active drug
10/10/2002US20020147203 Tyrosine kinase inhibitors
10/10/2002US20020147198 Substituted arylamine derivatives and methods of use
10/10/2002US20020147189 Immunology response; autoimmune disease
10/10/2002US20020147185 Antihypoxic agents, antiischamic agents, antiarrhythmia agents
10/10/2002US20020146805 DNA encoding the human serine protease T
10/10/2002US20020146466 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/10/2002US20020146463 Useful as food additives or in medicaments
10/10/2002US20020146417 Administering function blocking antibody or a fragment antibody, capable of binding an epitope of VLA-1 to provide a decrease in arthritic score of about 65% or greater when compared to control antibody treated subject
10/10/2002CA2442525A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002CA2442484A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002CA2442354A1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
10/10/2002CA2442150A1 Sapogenin derivatives, their synthesis and use, and methods based upon their use
10/10/2002CA2442064A1 G-protein coupled receptors
10/10/2002CA2442062A1 Secreted proteins
10/10/2002CA2441654A1 Cytoskeleton-associated proteins
10/10/2002CA2441562A1 Short bioactive peptides and methods for their use
10/10/2002CA2441077A1 Substituted carbazoles as inhibitors of spla2
10/10/2002CA2439842A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
10/10/2002CA2438272A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/09/2002EP1247809A2 Triazine compounds useful as sorbitol dehydrogenase inhibitors
10/09/2002EP1247532A1 Composition promoting lacrimal secretion
10/09/2002EP1247526A1 Perfusion liquid preparations for ophthalmic operations
10/09/2002EP1246843A1 Novel fgf homolog zfgf12
10/09/2002EP1246842A1 Nk cell receptor polynucleotides, polypeptides, and antibodies
10/09/2002EP1246828A1 Benzosulfones with calcium antagonist activity
10/09/2002EP1246823A1 Pyrimidine and triazine kinase inhibitors
10/09/2002EP1246799A1 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/09/2002EP1246790A1 Substituted 1 and 2 naphthol mannich bases
10/09/2002EP1246642A2 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
10/09/2002EP1246630A1 Compositions and methods for facilitating skin growth and managing skin conditions
10/09/2002EP1246629A1 Methods of using electron active compounds for managing cancer
10/09/2002EP1246628A1 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
10/09/2002EP1246627A2 Polyanhydrides with biologically active degradation products
10/09/2002EP1246623A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
10/09/2002EP1246621A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
10/09/2002EP1246605A2 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow
10/09/2002EP1049467B1 Celecoxib compositions
10/09/2002EP0973550B1 Antagonistic anti-avb3 integrin antibodies
10/09/2002EP0897301B1 Method of treating otitis media with uridine triphosphates and related compounds
10/09/2002EP0868434B1 Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs
10/09/2002EP0837686B1 Use of indigestible oligosaccharides to treat and prevent otitis media in humans
10/09/2002EP0825863B1 Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
10/09/2002CN1373763A Pteridinones and kinase inhibitors
10/09/2002CN1373760A Quinuclidine derivs. as muscarinic M3 receptors ligand and their use
10/09/2002CN1373752A Prostaglandin derivs.
10/09/2002CN1373751A 'Alpha'-amino-'beta'-sulfonyl hydroxamic acid compounds
10/09/2002CN1373661A Ophthalmic fluid
10/09/2002CN1373126A Crystallization formed N-(4-trifluoromethylphenyl)-5-methyl isooxazo-4-carboxamide
10/09/2002CN1092049C Composition for treating late allergic reactions and inflammation diseases, and use thereof
10/08/2002US6462198 Used in the control or prevention of acute and/or chronic neurological disorders such as restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia,
10/08/2002US6462082 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery
10/08/2002US6462061 Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for treatment of dry eye
10/08/2002US6462060 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/08/2002US6462057 Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
10/08/2002US6462047 Containing 5- or 6-membered oxygen, nitrogen and/or sulfur heteroaryl group; angina, hypertension, respiratory distress, congestive heart failure, renal failure, atherosclerosis, inflammatory diseases, strokes, bronchitis, asthma
10/08/2002US6462036 Inhibiting signal transduction by modulating activity of receptor and nonreceptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism
10/08/2002US6461642 Crystallization using supercritical or subcritical fluids
10/08/2002CA2196769C Benzimidazole derivatives having dopaminergic activity
10/08/2002CA2066083C Benzodiazepine analogs as cholecystokinin antagonists
10/03/2002WO2002077021A2 Streptococcus pneumoniae proteins and nucleic acids
10/03/2002WO2002077017A2 Medical uses of intercellular communication facilitating compounds
10/03/2002WO2002076995A2 2-amino-propanol derivatives
10/03/2002WO2002076986A1 Pyrazolopyrimidines as therapeutic agents
10/03/2002WO2002076983A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors
10/03/2002WO2002076979A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002WO2002076977A2 Rho-kinase inhibitors
10/03/2002WO2002076976A2 Rho-kinase inhibitors
10/03/2002WO2002076964A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
10/03/2002WO2002076963A1 Bicyclic guanidine derivatives and therapeutic uses thereof
10/03/2002WO2002076957A1 Activator for peroxisome proliferator-activated receptor
10/03/2002WO2002076950A2 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
10/03/2002WO2002076933A1 Formailide derivatives as beta2-adrenoreceptor agonists
10/03/2002WO2002076497A2 Method and composition
10/03/2002WO2002076486A2 Histidine-rich glycoprotein
10/03/2002WO2002076460A2 Use of propentofylline to control intraocular pressure
10/03/2002WO2002076450A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/03/2002WO2002076442A1 Stable aqueous liquid preparation
10/03/2002WO2002076438A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
10/03/2002WO2002076242A1 Nutritional supplement to treat macular degeneration
10/03/2002WO2002062784A8 Piperidinee derivatives as neurokinin 1 antagonists
10/03/2002WO2002046226A3 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
10/03/2002WO2002014349A3 Non-covalent inhibitors of urokinase and blood vessel formation
10/03/2002WO2001071004A3 Proteases
10/03/2002WO2001019800A9 Mediators of hedgehog signaling pathways, compositions and uses related thereto
10/03/2002US20020143054 Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
10/03/2002US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002US20020143026 Induce mitotic arrest thereby making them useful as anti-cancer agents; also for therapy of diseases which can be treated by inducing mitotic arrest
10/03/2002US20020143009 Novel bicyclic oxazolidinones as antibacterial agents
10/03/2002US20020143004 Allosteric adenosine receptor modulators
1 ... 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 ... 531